New Liver Aging Index Predicts Mortality Better Than Chronological Age
A noninvasive 13-variable score reveals how fast your liver is aging — and accelerated liver aging raises mortality risk by up to 85%.
Summary
Researchers developed the Liver Aging Index (LAI), a noninvasive score combining routine clinical measurements, blood biomarkers, and liver imaging to estimate biological aging of the liver. Validated across three large cohorts totaling over 37,000 individuals from 16 global centers, the LAI outperformed chronological age in predicting mortality. People whose livers aged faster than expected faced up to 85% higher all-cause mortality risk and up to 170% higher risk of liver-related death or disease events. Genetic analysis further showed that inherited predisposition to accelerated liver aging sharply elevated risks of cirrhosis and liver cancer. Unexpectedly, the amyloid-beta clearance pathway — better known for its role in Alzheimer's — emerged as a novel mechanism in liver aging.
Detailed Summary
Liver disease is a growing global health burden, yet there has been no reliable, noninvasive way to measure how biologically old a person's liver actually is — until now. Understanding biological rather than chronological age of specific organs could transform early risk detection and guide therapeutic decisions far earlier than conventional diagnosis.
Researchers from Peking University and collaborators worldwide developed the Liver Aging Index (LAI) using data from 21,629 participants in the China Kadoorie Biobank. The LAI incorporates 13 variables: three clinical factors (BMI, systolic and diastolic blood pressure), eight standard plasma biomarkers (including liver enzymes, lipids, and glucose), and two imaging measurements of liver fat and stiffness obtainable via vibration-controlled transient elastography (FibroScan).
The LAI was externally validated in NHANES (N=3,412) and the VCTE-Prognosis cohort (N=12,170, spanning 16 international centers). Across all cohorts, the LAI achieved strong discrimination for all-cause mortality (AUROC ~0.76), significantly outperforming chronological age. A derived metric — Liver Aging Acceleration (LAA), the gap between LAI and chronological age — showed that each one standard-deviation increase in LAA was associated with 22–85% higher all-cause mortality risk and 34–170% higher liver-related event or death risk.
Genetic analyses using instruments derived from the CKB cohort found that genetic predisposition to faster liver aging was linked to a nearly fourfold higher risk of cirrhosis and nearly eightfold higher risk of liver cancer, with findings replicated in Biobank Japan. Integrating genomic and proteomic data also implicated the amyloid-beta clearance pathway and amyloid precursor protein in liver aging — a surprising connection that may open new mechanistic research avenues.
The LAI offers a clinically practical, noninvasive tool that could be integrated into routine metabolic health assessments. Caveats include reliance on abstract-only data, requirement for specialized liver imaging, and the need for prospective interventional studies to determine whether reducing LAA improves outcomes.
Key Findings
- The Liver Aging Index (LAI) predicted all-cause mortality better than chronological age across 37,000+ individuals globally.
- Each 1-SD increase in liver aging acceleration raised all-cause mortality risk by 22–85% depending on cohort.
- Accelerated liver aging was linked to up to 170% higher risk of liver-related death or disease events.
- Genetic predisposition to faster liver aging raised cirrhosis risk ~4x and liver cancer risk ~8x.
- The amyloid-beta clearance pathway was unexpectedly identified as a novel mechanism in liver biological aging.
Methodology
The LAI was developed in 21,629 CKB participants using a Cox-Gompertz proportional hazards model incorporating 13 clinical, biochemical, and imaging variables. It was externally validated in two independent cohorts: NHANES (N=3,412) and a multinational VCTE-Prognosis cohort (N=12,170, 16 centers). Genetic Mendelian randomization and proteomics were used to explore mechanistic pathways.
Study Limitations
This summary is based on the abstract only, as the full text was not available; finer methodological details, model coefficients, and subgroup analyses could not be reviewed. The LAI requires liver imaging (fat attenuation parameter and liver stiffness measurement) not universally available in all clinical settings. Causality cannot be firmly established from observational data, and interventional trials are needed to confirm whether reducing liver aging acceleration improves clinical outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.